130 related articles for article (PubMed ID: 17850871)
1. Immunogenicity and therapeutic efficacy of phage-displayed beta-amyloid epitopes.
Esposito M; Luccarini I; Cicatiello V; De Falco D; Fiorentini A; Barba P; Casamenti F; Prisco A
Mol Immunol; 2008 Feb; 45(4):1056-62. PubMed ID: 17850871
[TBL] [Abstract][Full Text] [Related]
2. Active immunization against Alzheimer's beta-amyloid peptide using phage display technology.
Solomon B
Vaccine; 2007 Apr; 25(16):3053-6. PubMed ID: 17287054
[TBL] [Abstract][Full Text] [Related]
3. Generation of anti-beta-amyloid antibodies via phage display technology towards Alzheimer's disease vaccination.
Solomon B
Vaccine; 2005 Mar; 23(17-18):2327-30. PubMed ID: 15755621
[TBL] [Abstract][Full Text] [Related]
4. Generation of anti-beta-amyloid antibodies via phage display technology.
Frenkel D; Dori M; Solomon B
Vaccine; 2004 Jun; 22(19):2505-8. PubMed ID: 15193416
[TBL] [Abstract][Full Text] [Related]
5. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease.
Bard F; Cannon C; Barbour R; Burke RL; Games D; Grajeda H; Guido T; Hu K; Huang J; Johnson-Wood K; Khan K; Kholodenko D; Lee M; Lieberburg I; Motter R; Nguyen M; Soriano F; Vasquez N; Weiss K; Welch B; Seubert P; Schenk D; Yednock T
Nat Med; 2000 Aug; 6(8):916-9. PubMed ID: 10932230
[TBL] [Abstract][Full Text] [Related]
6. Towards Alzheimer's beta-amyloid vaccination.
Frenkel D; Solomon B
Biologicals; 2001; 29(3-4):243-7. PubMed ID: 11851323
[TBL] [Abstract][Full Text] [Related]
7. Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology.
Bard F; Barbour R; Cannon C; Carretto R; Fox M; Games D; Guido T; Hoenow K; Hu K; Johnson-Wood K; Khan K; Kholodenko D; Lee C; Lee M; Motter R; Nguyen M; Reed A; Schenk D; Tang P; Vasquez N; Seubert P; Yednock T
Proc Natl Acad Sci U S A; 2003 Feb; 100(4):2023-8. PubMed ID: 12566568
[TBL] [Abstract][Full Text] [Related]
8. In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques.
Poduslo JF; Ramakrishnan M; Holasek SS; Ramirez-Alvarado M; Kandimalla KK; Gilles EJ; Curran GL; Wengenack TM
J Neurochem; 2007 Jul; 102(2):420-33. PubMed ID: 17596213
[TBL] [Abstract][Full Text] [Related]
9. Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers.
Meli G; Visintin M; Cannistraci I; Cattaneo A
J Mol Biol; 2009 Apr; 387(3):584-606. PubMed ID: 19361429
[TBL] [Abstract][Full Text] [Related]
10. Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer's disease.
Wang CY; Finstad CL; Walfield AM; Sia C; Sokoll KK; Chang TY; Fang XD; Hung CH; Hutter-Paier B; Windisch M
Vaccine; 2007 Apr; 25(16):3041-52. PubMed ID: 17287052
[TBL] [Abstract][Full Text] [Related]
11. The immune system, amyloid-beta peptide, and Alzheimer's disease.
Weksler ME; Gouras G; Relkin NR; Szabo P
Immunol Rev; 2005 Jun; 205():244-56. PubMed ID: 15882358
[TBL] [Abstract][Full Text] [Related]
12. Polypeptide conjugates comprising a beta-amyloid plaque-specific epitope as new vaccine structures against Alzheimer's disease.
Manea M; Mezö G; Hudecz F; Przybylski M
Biopolymers; 2004; 76(6):503-11. PubMed ID: 15499564
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy as treatment for Alzheimer's disease.
Hawkes CA; McLaurin J
Expert Rev Neurother; 2007 Nov; 7(11):1535-48. PubMed ID: 17997702
[TBL] [Abstract][Full Text] [Related]
14. Recombinant GST-I-A beta 28-induced efficient serum antibody against A beta 42.
Huang X; Wang J; Cui L; Zou X; Zhang Y
J Neurosci Methods; 2010 Jan; 186(1):52-9. PubMed ID: 19900475
[TBL] [Abstract][Full Text] [Related]
15. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning.
Schenk D
Nat Rev Neurosci; 2002 Oct; 3(10):824-8. PubMed ID: 12360327
[No Abstract] [Full Text] [Related]
16. Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies.
Lee M; Bard F; Johnson-Wood K; Lee C; Hu K; Griffith SG; Black RS; Schenk D; Seubert P
Ann Neurol; 2005 Sep; 58(3):430-5. PubMed ID: 16130106
[TBL] [Abstract][Full Text] [Related]
17. Modulation of Alzheimer's pathology by cerebro-ventricular grafting of hybridoma cells expressing antibodies against Abeta in vivo.
Gaugler MN; Tracy J; Kuhnle K; Crameri A; Nitsch RM; Mohajeri MH
FEBS Lett; 2005 Jan; 579(3):753-6. PubMed ID: 15670841
[TBL] [Abstract][Full Text] [Related]
18. Species-specific immune response to immunization with human versus rodent A beta peptide.
Seabrook TJ; Bloom JK; Iglesias M; Spooner ET; Walsh DM; Lemere CA
Neurobiol Aging; 2004 Oct; 25(9):1141-51. PubMed ID: 15312960
[TBL] [Abstract][Full Text] [Related]
19. Design, structural, and immuno-analytical properties of antigenic bioconjugates comprising a beta-amyloid-plaque specific epitope.
Manea M; Przybylski M; Hudecz F; Mezö G
Biopolymers; 2008; 90(2):94-104. PubMed ID: 18183582
[TBL] [Abstract][Full Text] [Related]
20. Single-domain antibodies recognize selectively small oligomeric forms of amyloid beta, prevent Abeta-induced neurotoxicity and inhibit fibril formation.
Lafaye P; Achour I; England P; Duyckaerts C; Rougeon F
Mol Immunol; 2009 Feb; 46(4):695-704. PubMed ID: 18930548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
